Back to top

["Medication, Administered": "Unfractionated Heparin"]

Performance/Reporting Period
Value Set Description from VSAC
Clinical Focus: This value set contains concepts that represent heparin formulations that could reasonably be used to treat venous thromboembolism as a continuous infusion.
Data Element Scope: This value set may use the Quality Data Model (QDM) category related to Medication. The intent of this data element is to identify patients who receive unfractionated heparin as an intravenous infusion.
Inclusion Criteria: Includes only relevant concepts associated with injectable products that could reasonably be used for continuous infusion of heparin and achieve therapeutic levels.
Exclusion Criteria: Excludes concentrations < 250 UNT/ML (except those representing premixed heparin infusion bags, per inclusion criteria).

Constrained to codes in the Medication, Administered: Unfractionated Heparin value set (2.16.840.1.113883.

QDM Datatype and Definition (QDM Version 5.4)

"Medication, Administered"

Data elements that meet criteria using this datatype should document that the medication indicated by the QDM category and its corresponding value set was actually administered to the patient.

Timing: The Relevant Period addresses:

  • startTime - when a single medication administration event starts (e.g., the initiation of an intravenous infusion, or administering a pill or IM injection to a patient),
  • stopTime - when a single medication administration event ends (e.g., the end time of the intravenous infusion, or the administration of a pill or IM injection is completed - for pills and IM injections, the start and stop times are the same)

NOTE – Measure developers should address multiple administrations over a period of time using CQL logic.

QDM Attributes


The time the data element was entered into the clinical software. Note, some datatypes include both Relevant Time and Author dateTime attributes. The purpose is to accommodate Author dateTime if the actual start and stop times are not available when evaluating for feasibility, and also to allow specification of a time for Negation Rationale.


Refers to the path by which the medication or substance should be taken into the body system, such as intradermally, intrathecally, intramuscularly, intranasally, intravenously, orally, rectally, subcutaneously, sublingually, topically, or vaginally.
Last Updated: Jul 08, 2021